SoFi Blog

IPO investing is officially live! Now you can Invest in IPOs before they’re traded on a public market—only in the SoFi app. Want to see how it all works?

Ledger, Faire, and Mythical Games raised venture funding this week. Learn why investors are betting on these three startups.

Roblox just got slapped with a $200 million-plus lawsuit by the National Music Publishers’ Association. Learn more here.

The CPI rose 5% in May, marking its biggest increase since August 2008. Learn what is driving prices higher and why the Fed probably will not respond.

Social Capital Suvretta Holdings Corp. I (DNAA)

Social Capital Suvretta Holdings Corp. I is a newly incorporated blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The management team is led by Chamath Palihapitiya, Chairman of the board of directors and Chief Executive Officer, and Kishen Mehta, the President and one of the directors.

While they may pursue an initial business combination target in any industry, subsector therein or geographic location (subject to certain limitations described in the prospectus), they intend to focus their search for a target business operating in the biotechnology industry and within the neurology subsector of such industry, that has a focus on identifying therapeutics, novel platforms and other modalities to help manage and treat brain and nervous system disorders, including neurologic and psychiatric diseases and pain management.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.

Social Capital Suvretta Holdings Corp. II (DNAB)

Social Capital Suvretta Holdings Corp. II is a newly incorporated blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The management team is led by Chamath Palihapitiya, Chairman of the board of directors and Chief Executive Officer, and Kishen Mehta, the President and one of the directors.

While they may pursue an initial business combination target in any industry, subsector therein or geographic location (subject to certain limitations described in this prospectus), they intend to focus their search for a target business operating in the biotechnology industry and within the oncology subsector of such industry, that has a focus on identifying therapeutics, novel platforms and other modalities to help manage and treat cancer.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.

Social Capital Suvretta Holdings Corp. III (DNAC)

Social Capital Suvretta Holdings Corp. III is a newly incorporated blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The management team is led by Chamath Palihapitiya, Chairman of the board of directors and Chief Executive Officer, and Kishen Mehta, the President and one of the directors.

While they may pursue an initial business combination target in any industry, subsector therein or geographic location (subject to certain limitations described in this prospectus), they intend to focus their search for a target business operating in the biotechnology industry and within the organ space subsector of such industry, that has a focus on identifying therapeutics, novel platforms and other modalities to help manage and treat disorders related to cardiology, nephrology, ophthalmology, hematology and endocrinology.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.

Social Capital Suvretta Holdings Corp. IV (DNAD)

Social Capital Suvretta Holdings Corp. IV is a newly incorporated blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The management team is led by Chamath Palihapitiya, Chairman of the board of directors and Chief Executive Officer, and Kishen Mehta, the President and one of the directors.

While they may pursue an initial business combination target in any industry, subsector therein or geographic location (subject to certain limitations described in this prospectus), they intend to focus their search for a target business operating in the biotechnology industry and within the immunology subsector of such industry, that has a focus on identifying therapeutics, novel platforms and other modalities that treat immunology and inflammation disorders.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.